MRD Testing Emerges as Key Tool for Value-Based Care in Multiple Myeloma Treatment
核心洞察
Measurable residual disease (MRD) testing could enhance value-based care in multiple myeloma (搜索) by enabling personalized treatment decisions, including tailored maintenance therapy and avoiding overtreatment in patients with deep responses.
Clinical trials such as MASTER, MIDAS, PERSEUS, and GRIFFIN serve as models for risk-adapted consolidation and maintenance decisions using MRD testing to guide treatment strategies.
Significant barriers to routine MRD implementation include high costs, particularly for next-generation sequencing, lack of standardized protocols, and inconsistent insurance coverage for repeated testing.
Measurable residual disease (MRD) testing is positioned to transform value-based care in multiple myeloma (搜索) by enabling more personalized treatment decisions, according to experts discussing the technology's potential at a recent Institute for Value-Based Medicine (搜索)® event.
Emilie Aschenbrenner, PharmD, BCOP, a hematology coordinator and clinical oncology pharmacist at Froedtert Health (搜索) and the Medical College of Wisconsin in Milwaukee, outlined how MRD testing could guide real-world treatment strategies similar to risk-adapted approaches used in acute lymphoblastic leukemia (搜索).
Clinical Applications and Treatment Personalization
MRD testing, already established as a surrogate endpoint in clinical trials, could inform several key treatment decisions in multiple myeloma (搜索) care. Aschenbrenner noted that the technology could enable tailoring maintenance therapy, avoiding overtreatment in patients with deep, durable responses, and intensifying therapy for those with less robust responses.
Several ongoing clinical trials provide models for implementing MRD-guided care. The MASTER trial (NCT03224507), MIDAS trial (NCT04934475), PERSEUS trial (NCT03710603), and GRIFFIN trial (NCT02874742) demonstrate risk-adapted consolidation and maintenance decision-making based on MRD results.
"We talked about, certainly, modeling after the MASTER trial, or there's a MIDAS trial for risk-adapted consolidation, also PERSEUS and GRIFFIN trials, where we can tailor maintenance, where not all patients may need a dual maintenance therapy for multiple years," Aschenbrenner explained.
Health System Benefits and Cost Implications
From a health system perspective, achieving MRD negativity earlier could reduce healthcare utilization and costs. Aschenbrenner emphasized that patients with deep, durable responses who achieve MRD negativity may require fewer infusion visits and experience reduced hospitalizations for complications such as infections.
"If we are able to get certain patients at different end points, like after induction or consolidation, for example, to have deep and durable responses and be MRD negative, then they don't have to show up to infusion clinic as often or have hospitalizations for infection," she said.
Ravi Vij, MD, MBA, professor of medicine in the Division of Medical Oncology at Washington University School of Medicine, noted that MRD-guided care could help reduce costs, minimize treatment-related toxicity, and extend the durability of disease control for many patients once sufficient data become available.
Current Status Across Hematologic Malignancies
The predictive value of MRD testing varies across different blood cancers. Vij explained that in acute lymphoblastic leukemia (搜索) and some cases of chronic lymphocytic leukemia (搜索), MRD testing is already both prognostic and predictive, allowing clinicians to make treatment decisions based on results.
"In multiple myeloma (搜索), we are getting there slowly, but at the moment it's more a prognostic marker," Vij said. "Algorithms have to be vetted on whether giving more patients more treatment if they are MRD positive to drive them to deeper levels of response or abbreviating treatment for those who have sustained MRD negativity is going to cut down on costs and the toxicity of the treatment."
Implementation Barriers and Access Challenges
Despite its potential, significant obstacles limit routine MRD testing implementation in clinical practice. High costs represent a primary barrier, particularly for next-generation sequencing approaches. The lack of standardized protocols and inconsistent insurance coverage for repeated testing throughout treatment courses further complicate adoption.
"These are very costly tests, especially next generation sequencing," Aschenbrenner noted. "Right now, as it's not standardized in clinical practice, it's really hard even for our community partners to offer those routinely to all patients."
Access disparities exist between academic centers and community practices. Academic institutions often have better access to MRD testing through clinical trials or manufacturer support programs. When insurance companies deny coverage for testing at specific timepoints, manufacturers may provide write-offs or coverage support.
However, community practices face greater challenges in offering routine MRD testing to all patients, particularly those without access to large academic centers. This limitation could create disparities in care quality and treatment optimization.
Future Outlook
Experts anticipate that as MRD testing becomes established as a surrogate endpoint for progression-free survival and overall survival, economies of scale will drive down testing costs. Standardization of MRD testing protocols and broader insurance coverage will be necessary for widespread clinical implementation.
The development of validated algorithms determining when to intensify therapy for MRD-positive patients or abbreviate treatment for those with sustained MRD negativity will be crucial for realizing the full potential of MRD-guided care in multiple myeloma (搜索) treatment.